<DOC>
	<DOCNO>NCT02096107</DOCNO>
	<brief_summary>Transition tacrolimus base triple therapy Mycophenolate Mofetil ( MMF ) steroids stable renal transplant patient low intensity tacrolimus , everolimus prednisone associate improvement Glomular Filtration Rate ( GFR ) allograft fibrosis .</brief_summary>
	<brief_title>Novartis Everolimus Transition</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Lung Diseases , Interstitial</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>1 . At least 18 year age able give inform consent . 2 . Received first repeat cadaveric ( include ECD ) live donor renal transplant . 3 . Patient stable graft function , define change great 40 % baseline serum creatinine acute rejection past month . 4 . Currently receive tacrolimus , mycophenolate mofetil prednisone immunosuppression regimen 1 . Biopsy proven acute rejection episode occur within past month . 2 . Malignancy within past 3 year , except nonmelanoma skin cancer . 3 . Currently enrol investigational drug trial . 4 . Woman child bear potential utilizing effective form birth control . 5 . Patients uncontrolled dyslipidemia , define serum fast LDL &gt; 200 mg/dL serum fast triglyceride &gt; 500 mg/dL . 6 . Patients spot urine protein creatinine ratio &gt; 800 mg protein per gram creatinine . 7 . WBC &lt; 2,000 cells/mm3 8 . Platelets &lt; 75,000 cells/mm3 9 . Patients receive organ transplant kidney . 10 . Patients history biopsy proven FSGS , MPGN , PGN .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Everolimus</keyword>
	<keyword>Graft dysfunction</keyword>
	<keyword>Interstitial fibrosis</keyword>
</DOC>